Oct 3 (Reuters) - U.S. health regulators approved PfizerInc's menopause drug Duavee, which the company hopeswill reduce hot flashes with fewer side effects than olderhormone-replacement therapies.
The Food and Drug Administration said on Thursday itapproved the drug to treat women with moderate to severemenopause symptoms and to prevent post-menopausal osteoporosis,a bone disease which can increase the risk of fractures.
The drug, which Pfizer is developing with LigandPharmaceuticals Inc, combines bazedoxifene - whichbelongs to a class of drugs known as selective estrogen receptormodulators, or SERMS - and conjugated estrogens, which arederived from the urine of pregnant horses and contained inPfizer's menopause drug Premarin.
- Health Care Industry
- Food and Drug Administration
- Pfizer Inc